Phase 3 Readout~month
Phase 3 Topline: A Phase 2/3 Multicenter, Open-label, Randomized, Active-Control Study of Zilovertamab Vedotin (MK-21
- Company
- Merck & Co., Inc. (MRK)
- Drug
- zilovertamab
- Indication
- DLBCL; Diffuse Large B-Cell Lymphoma
Other upcoming events for MRK
Phase 2 StartPhase 2 Start: A Phase 2, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate the Safety, Tolerabilit
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and S
Phase 3 ReadoutPhase 3 Topline: Open-label, Individual Dose Titration Study to Evaluate Safety, Tolerability and Pharmacokinetics of
Track this catalyst and more
Get real-time alerts, AI-powered analysis, and full catalyst coverage.